Novel Therapeutics Targeting Disease/Tissue-specific Macrophage Biology with a Focus on Regeneration and Clearance

Astellas Pharma Inc. is seeking novel research programmes targeting disease/tissue-specific macrophage biology with a focus on regeneration and clearance.

Approaches of Interest

Priority will be given to opportunities fulfilling one or more of the criteria given below:

- **Biology**: Disease/tissue-specific macrophage (e.g. M1/M2, Mreg), regeneration (e.g. functional recovery, tissue regeneration, modulation of macrophage phenotype by extracellular vesicle therapy, cell therapy), clearance (e.g. phagocytosis, lysosome, degradation)
- **Modality**: Broad interest in all modalities, such as small molecules, antibodies, extracellular vesicle therapy, cell therapy, gene therapy, and targeted protein degradation approaches
- **Target disease**: Immune-mediated diseases, peripheral and/or central neuroinflammatory disorders, autoimmune diseases, and hearing loss are prioritised. Highly creative proposals in other diseases are also within scope
- **Therapeutic target**: Mechanism of action is proven or well-understood

Out of Scope

- Microbiome focused approaches, well-known target approaches, steroids, natural products and drug repurposing

Stage of Development

- Opportunities from the lead optimisation stage through to Clinical Phase II is within scope
- Priority will be given to opportunities where preclinical proof of concept has been evaluated in a clinically translatable study (e.g. *in vitro* patient-derived/human/mammalian cells/tissues assays, *in vivo* animal model studies)

Submission Information

- Submission of one-page, 200-300 word briefs are encouraged; in submitting to this campaign, you confirm that your submission contains only non-confidential information
- Astellas Pharma Inc. is open to a range of collaboration opportunities decided on a case-by-case basis, with a main focus on developing new research programme collaborations

Opportunities sought

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](http://discover.in-part.com)

Deadline: 7th March 2022 - 11:59 pm GMT

Have any questions? Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)